Hebei Changshan Biochemical Pharmaceutical Co Ltd

Chart & Performance

D1W1MN

P/E

—

P/S

59.70

EPS

—

Div Yield, %

—

Shrs. gr., 5y

-0.24%

Rev. gr., 5y

-13.03%

Revenues

1.03b

-26.92%

Net income

-249m

L-79.88%

CFO

56m

+66.69%

Dividend

Jun 27, 20230.005 CNY/sh

Notes

No notes on this company yet

Write a private note on this company, for your eyes only

Add note

Profile

Hebei Changshan Biochemical Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of crude heparin, heparin raw materials, and heparin preparations for the treatment of cardiovascular and cerebrovascular diseases in China. Its products include crude heparin sodium, heparin sodium raw materials, heparin sodium injections, low molecular weight heparin calcium raw materials and injections, enoxaparin sodium raw materials and injections, nadra Heparin calcium raw materials, nadroparin calcium injections, and dalteparin sodium raw materials and injections. The company was founded in 2000 and is based in Shijiazhuang, China.

URL

http://www.hbcsbio.com/

IPO date

Aug 19, 2011

Employees

Domiciled in

Incorporated in

Valuation

Order:

Title CNY in thousands, except ratios and share amounts	FY	FY	FY	FY	FY	FY	FY	FY	FY	FY
Title CNY in thousands, except ratios and share amounts	2024‑12	2023‑12	2022‑12	2021‑12	2020‑12	2019‑12	2018‑12	2017‑12	2016‑12	2015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT